Study title:
Shapira MY, Resnick IB, Chou S, Neumann AU, Lurain NS, Stamminger T,
Caplan O, Saleh N, Efferth T, Marschall M, Wolf
DG. Artesunate as a potent antiviral agent in a patient with late drug resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis. 2008 May 1;46(9):1455-7.Shapira MY, Resnick IB, Chou S, Neumann AU, Lurain NS, Stamminger T,
Caplan O, Saleh N, Efferth T, Marschall M, Wolf
DG. Artesunate as a potent antiviral agent in a patient with late drug resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis. 2008 May 1;46(9):1455-7.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Virus Diseases [C02]
|
Brands: Please see report, Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: Foscarnet |
ATC code: |
Document link:
Shapira MY et al 2008.pdf
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|